PMID- 37766173 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20230930 IS - 2076-393X (Print) IS - 2076-393X (Electronic) IS - 2076-393X (Linking) VI - 11 IP - 9 DP - 2023 Sep 16 TI - A Field Efficacy Trial of Recombinant Porcine Circovirus Type 2d Vaccine in Three Herds. LID - 10.3390/vaccines11091497 [doi] LID - 1497 AB - This study aimed to evaluate the efficacy of a virus-like particle (VLP) vaccine containing the open reading frame 2 of porcine circovirus type 2d (PCV2d) in a farm environment where natural infections associated with porcine circovirus-associated disease are endemic. The vaccine trial was conducted on three farms (H, M, and Y) with a history of infections including porcine reproductive and respiratory syndrome virus (PRRSV), PCV, Mycoplasma, and E. coli. Farm H, as well as farms M and Y, experienced natural PCV2 infection between 4 and 8 weeks post-vaccination (wpv), and 8 and 12 wpv, respectively. Viremia levels of all farms were significantly (p < 0.05) lower in vaccinated piglets than the control group after natural infection. In all farms, serum immunoglobulin G levels peaked at 8 wpv in the vaccinated groups, surpassing those in the control groups. Furthermore, neutralizing antibody titers were significantly (p < 0.05) higher in the vaccinated groups than the control groups in farms H and Y (0-8 wpv). However, there were no significant differences between the vaccinated and control group in neutralizing antibody titers of farm M (0-20 wpv). In terms of body weight, vaccinated piglets from all three farms showed significantly increased average weights at 12 wpv compared to the control groups. In conclusion, our study revealed noteworthy differences in viremia and body weight gain between vaccinated and control animals on three farms. As a result, this field trial of PCV2d VLP vaccine was successful in protecting piglets from natural PCV2 infection. FAU - Ju, Lanjeong AU - Ju L AD - Division of Viral Diseases, Animal and Plant Quarantine Agency, 177, Gimcheon-si 39660, Gyeongsangbuk-do, Republic of Korea. FAU - Jayaramaiah, Usharani AU - Jayaramaiah U AD - Division of Viral Diseases, Animal and Plant Quarantine Agency, 177, Gimcheon-si 39660, Gyeongsangbuk-do, Republic of Korea. FAU - Lee, Min-A AU - Lee MA AD - Division of Viral Diseases, Animal and Plant Quarantine Agency, 177, Gimcheon-si 39660, Gyeongsangbuk-do, Republic of Korea. FAU - Jeong, Young-Ju AU - Jeong YJ AD - Technology Institute, KBNP, Anyang-si 14059, Gyeonggi-do, Republic of Korea. FAU - You, Su-Hwa AU - You SH AD - Division of Viral Diseases, Animal and Plant Quarantine Agency, 177, Gimcheon-si 39660, Gyeongsangbuk-do, Republic of Korea. FAU - Lee, Hyang-Sim AU - Lee HS AD - Division of Viral Diseases, Animal and Plant Quarantine Agency, 177, Gimcheon-si 39660, Gyeongsangbuk-do, Republic of Korea. FAU - Hyun, Bang-Hun AU - Hyun BH AD - Division of Viral Diseases, Animal and Plant Quarantine Agency, 177, Gimcheon-si 39660, Gyeongsangbuk-do, Republic of Korea. FAU - Lee, Nakhyung AU - Lee N AD - Technology Institute, KBNP, Anyang-si 14059, Gyeonggi-do, Republic of Korea. FAU - Kang, Seok-Jin AU - Kang SJ AD - Division of Viral Diseases, Animal and Plant Quarantine Agency, 177, Gimcheon-si 39660, Gyeongsangbuk-do, Republic of Korea. LA - eng GR - M-1543083-2019-21, M-1543083-2022-23-01/Animal and Plant Quarantine Agency/ PT - Journal Article DEP - 20230916 PL - Switzerland TA - Vaccines (Basel) JT - Vaccines JID - 101629355 PMC - PMC10538009 OTO - NOTNLM OT - efficacy OT - field trial OT - piglets OT - porcine circovirus-associated disease OT - recombinant porcine circovirus type 2d vaccine COIS- The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results. EDAT- 2023/09/28 06:42 MHDA- 2023/09/28 06:43 PMCR- 2023/09/16 CRDT- 2023/09/28 01:44 PHST- 2023/07/26 00:00 [received] PHST- 2023/09/01 00:00 [revised] PHST- 2023/09/14 00:00 [accepted] PHST- 2023/09/28 06:43 [medline] PHST- 2023/09/28 06:42 [pubmed] PHST- 2023/09/28 01:44 [entrez] PHST- 2023/09/16 00:00 [pmc-release] AID - vaccines11091497 [pii] AID - vaccines-11-01497 [pii] AID - 10.3390/vaccines11091497 [doi] PST - epublish SO - Vaccines (Basel). 2023 Sep 16;11(9):1497. doi: 10.3390/vaccines11091497.